Targeting colorectal cancer with targeted therapies: Pathways
Keywords:
Cancer, Personalized medicine, therapeutic outcome, tumor.Abstract
Colorectal cancer (CRC), one of the world's most prevalent and deadliest tumors, resulted in around 881,000 melanoma fatalities in 2018. Colorectal cancer (CRC) is the third-most common cause of all cancer-related deaths globally. The ensuing side effects brought on by the toxicity of conventional drugs are a challenging problem associated with chemotherapy. It is understandably problematic to deliver chemotherapeutic medications precisely to the affected site of something like the colon in a predictable and dependable manner. Chemotherapy and surgery were the only options available to cancer patients for a long time. The prognosis for CRC has never been good, especially for patients with metastatic cancers. Targeted therapy, a recent optional method, has been successful in extending the overall survival of CRC patients. Following successes with the anti-EGFR (epidermal growth factor receptor) drug cetuximab and the anti-angiogenesis drug bevacizumab, new medications that inhibit a variety of critical pathways and immunological checkpoints are being developed at an unheard-of rate. Guidelines for the recommended targeted drugs are being updated globally based on the growing body of high-quality clinical research. This study provides a summary of the present CRC-targeted medications and their underlying mechanisms, along with a discussion of their shortcomings and potential future possibilities.
Keywords: Chemotherapeutic medicines, Bevacizumab, Cetuximab, Colorectal cancer
Downloads
References
R. Labianca, G.D. Beretta, B. Kildani, L. Milesi, F. Merlin, S. Mosconi, M.A. Pessi, T. Prochilo, A. Quadri, G. Gatta, Colon cancer, Critical reviews in oncology/hematology 74(2) (2010) 106-133.
S.D. Markowitz, D.M. Dawson, J. Willis, J.K. Willson, Focus on colon cancer, Cancer cell 1(3) (2002) 233-236.
R.J. Lihite, M. Lahkar, S. Das, D. Hazarika, M. Kotni, M. Maqbool, S. Phukan, A study on adverse drug reactions in a tertiary care hospital of Northeast India, Alexandria journal of medicine 53(2) (2017) 151-156.
M. Maqbool, M.A. Dar, I. Gani, S.A. Mir, M. Khan, Herbal medicines as an alternative source of therapy: a review, World J Pharm Pharm Sci 3 (2019) 374-80.
P.F. Engstrom, J.P. Arnoletti, A.B. Benson, Y.-J. Chen, M.A. Choti, H.S. Cooper, A. Covey, R.A. Dilawari, D.S. Early, P.C. Enzinger, Colon cancer, Journal of the National Comprehensive Cancer Network 7(8) (2009) 778-831.
J. Terzić, S. Grivennikov, E. Karin, M. Karin, Inflammation and colon cancer, Gastroenterology 138(6) (2010) 2101-2114. e5.
A.B. Benson, J.P. Arnoletti, T. Bekaii-Saab, E. Chan, Y.-J. Chen, M.A. Choti, H.S. Cooper, R.A. Dilawari, P.F. Engstrom, P.C. Enzinger, Colon cancer, Journal of the National Comprehensive Cancer Network 9(11) (2011) 1238-1290.
M. Ahmed, Colon cancer: a clinician’s perspective in 2019, Gastroenterology research 13(1) (2020) 1-10.
M. Maqbool, M. Khan, M. Mohammad, M.A. Adesina, G. Fekadu, Awareness about reproductive health in adolescents and youth: a review, Journal of Applied Pharmaceutical Sciences and Research (2019) 1-5.
I. Ara, M. Maqbool, G. Fekadu, T.A. Hajam, M.A. Dar, Pharmaceutical significance of Nigella sativa L., a wonder herb, Journal of Applied Pharmaceutical Sciences and Research 3(4) (2020) 04-13.
I. Ara, M. Maqbool, I. Gani, Neuroprotective Activity of Herbal Medicinal Products: A Review, International Journal of Current Research in Physiology and Pharmacology (2022) 1-10.
R.W. Burt, Colon cancer screening, Gastroenterology 119(3) (2000) 837-853.
E. Giovannucci, Modifiable risk factors for colon cancer, Gastroenterology Clinics 31(4) (2002) 925-943.
P. Greenwald, Colon cancer overview, Cancer 70(S3) (1992) 1206-1215.
J.T. LaMont, T.A. O'Gorman, Experimental colon cancer, Gastroenterology 75(6) (1978) 1157-1169.
M. Zehravi, M. Maqbool, I. Ara, Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review, Open Health 3(1) (2022) 60-65.
J.M. Jessup, L.S. McGinnis, G.D. Steele, H.R. Menck, D.P. Winchester, The national cancer data base report on colon cancer, Cancer 78(4) (1996) 918-926.
L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, R. De Maria, Identification and expansion of human colon-cancer-initiating cells, Nature 445(7123) (2007) 111-115.
I. Ara, M. Maqbool, M. Zehravi, Psychic consequences of infertility on couples: A short commentary, Open Health 3(1) (2022) 114-119.
M.S. Cappell, Pathophysiology, clinical presentation, and management of colon cancer, Gastroenterology Clinics of North America 37(1) (2008) 1-24.
P.A. Newcomb, J. Baron, M. Cotterchio, S. Gallinger, J. Grove, R. Haile, D. Hall, J.L. Hopper, J. Jass, L. Le Marchand, Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer, Cancer epidemiology, biomarkers & prevention 16(11) (2007) 2331-2343.
I. Ara, M. Maqbool, I. Gani, Reproductive Health of Women: Implications and attributes, International Journal of Current Research in Physiology and Pharmacology (2022) 8-18.
M.A. Dar, I. Gani, I. Ara, Overview of substance use disorders and available treatments, Int. J. Curr. Res. Physiol. Pharmacol 7(2) (2023) 3-7.
M. Maqbool, M.A. Dar, I. Gani, S.A. Mir, Animal models in diabetes mellitus: an overview, Journal of Drug Delivery and Therapeutics 9(1-s) (2019) 472-475.
Y.-H. Xie, Y.-X. Chen, J.-Y. Fang, Comprehensive review of targeted therapy for colorectal cancer, Signal transduction and targeted therapy 5(1) (2020) 22.
M. El Bali, J. Bakkach, M. Bennani Mechita, Colorectal cancer: from genetic landscape to targeted therapy, Journal of Oncology 2021 (2021).
A. Majeed, R. Bashir, S. Farooq, M. Maqbool, Preparation, characterization and applications of nanoemulsions: An insight, Journal of Drug Delivery and Therapeutics 9(2) (2019) 520-527.
P. Hassanzadeh, Colorectal cancer and NF-κB signaling pathway, Gastroenterology and hepatology from bed to bench 4(3) (2011) 127.
T. Winder, H.J. Lenz, Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer, Gastroenterology 138(6) (2010) 2163-2176.
M. Mohd, M. Maqbool, M.A. Dar, I. Mushtaq, Polycystic ovary syndrome, a modern epidemic: an overview, Journal of Drug Delivery and Therapeutics 9(3) (2019) 641-644.
F. Li, C. Zhao, L. Wang, Molecular‐targeted agents combination therapy for cancer: developments and potentials, International journal of cancer 134(6) (2014) 1257-1269.
N. Simiantonaki, C. Jayasinghe, R. Michel-Schmidt, K. Peters, M.I. Hermanns, C.J. Kirkpatrick, Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines, International journal of oncology 32(3) (2008) 585-592.
M. Zehravi, M. Maqbool, I. Ara, Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview, International Journal of Adolescent Medicine and Health 33(6) (2021) 339-345.
Y. Zhou, H. Yan, M. Guo, J. Zhu, Q. Xiao, L. Zhang, Reactive oxygen species in vascular formation and development, Oxidative medicine and cellular longevity 2013 (2013).
D. Passaro, D. Bonnet, How to say NO to vascular disruption and stem cell mobilization, Expert Opinion on Therapeutic Targets 22(7) (2018) 563-565.
R. Maqbool, M. Maqbool, M. Zehravi, I. Ara, Menstrual distress in females of reproductive age: a literature review, International journal of adolescent medicine and health 34(2) (2021) 11-17.
R. Offringa, L. Kötzner, B. Huck, K. Urbahns, The expanding role for small molecules in immuno-oncology, Nature Reviews Drug Discovery (2022) 1-20.
A.K. Samadi, A. Bilsland, A.G. Georgakilas, A. Amedei, A. Amin, A. Bishayee, A.S. Azmi, B.L. Lokeshwar, B. Grue, C. Panis, A multi-targeted approach to suppress tumor-promoting inflammation, Seminars in cancer biology, Elsevier, 2015, pp. S151-S184.
L.S. Wood, N.P. Moldawer, M. Colleen Lewis, Immune checkpoint inhibitor therapy, Clinical Journal of Oncology Nursing 23(3) (2019) 271-280.
V. Kumar, N. Chaudhary, M. Garg, C.S. Floudas, P. Soni, A.B. Chandra, Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy, Frontiers in pharmacology 8 (2017) 49.
M. Maqbool, S. Rasool, M.A. Dar, R. Bashir, M. Khan, Hepatotoxicity and Hepatoprotective agents: A Mini review, PharmaTutor 7(9) (2019) 34-40.
K. Tajiri, M. Ieda, Cardiac complications in immune checkpoint inhibition therapy, Frontiers in Cardiovascular Medicine 6 (2019) 3.
J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau, M.S. Ernstoff, J.M. Gardner, P. Ginex, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology 36(17) (2018) 1714-1768.
M. Maqbool, M.A. Dar, I. Gani, S.A. Mir, M. Khan, A.U. Bhat, Maternal health and nutrition in pregnancy: an insight, World Journal of Pharmacy and Pharmaceutical Sciences 8(3) (2019) 450-459.
M.A. Morse, H. Hochster, A. Benson, Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy, The oncologist 25(1) (2020) 33-45.
I. Marquez-Rodas, P. Cerezuela, A. Soria, A. Berrocal, A. Riso, M. Gonzalez-Cao, S. Martin-Algarra, Immune checkpoint inhibitors: therapeutic advances in melanoma, Annals of translational medicine 3(18) (2015).
M. Maqbool, G. Fekadu, X. Jiang, F. Bekele, T. Tolossa, E. Turi, G. Fetensa, K. Fanta, An up to date on clinical prospects and management of osteoarthritis, Annals of Medicine and Surgery 72 (2021) 103077.
H. Abu-Sbeih, D.M. Faleck, B. Ricciuti, R.B. Mendelsohn, A.R. Naqash, J.V. Cohen, M.C. Sellers, A. Balaji, G. Ben-Betzalel, I. Hajir, Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease, Journal of Clinical Oncology 38(6) (2020) 576.
N. Li, X. Hou, S. Huang, R. Tai, L. Lei, S. Li, A. Abuliz, G. Wang, S. Yang, Biomarkers related to immune checkpoint inhibitors therapy, Biomedicine & Pharmacotherapy (2022) 112470.
M. Zehravi, M. Maqbool, I. Ara, Depression and anxiety in women with polycystic ovarian syndrome: a literature survey, International Journal of Adolescent Medicine and Health 33(6) (2021) 367-373.
J. Lee, J.H. Kim, Kaempferol inhibits pancreatic cancer cell growth and migration through the blockade of EGFR-related pathway in vitro, PloS one 11(5) (2016) e0155264.
T. Bai, Y. Liu, B. Li, LncRNA LOXL1‐AS1/miR‐let‐7a‐5p/EGFR‐related pathway regulates the doxorubicin resistance of prostate cancer DU‐145 cells, IUBMB life 71(10) (2019) 1537-1551.
I. Ara, M. Maqbool, B. Bukhari, N. Ara, T.A. Hajam, Present status, standardization and safety issues with herbal drugs, International Journal of Research in Pharmaceutical Sciences and Technology 1(3) (2020) 95-101.
M. Masuda, M. Suzui, J.T. Lim, A. Deguchi, J.W. Soh, I.B. Weinstein, Epigallocatechin‐3‐gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR‐related pathways of signal transduction, Journal of Experimental Therapeutics and Oncology 2(6) (2002) 350-359.
B. Guo, T. Zhang, J. Su, K. Wang, X. Li, Oxymatrine targets EGFR p-Tyr845 and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells, Cancer chemotherapy and pharmacology 75 (2015) 353-363.
M. Maqbool, G. Fekadu, D. Dugassa, F. Bekele, E. Turi, D. Simegnew, The pattern of substance abuse in the psychiatry department of a tertiary care of Srinagar hospital, Jammu and Kashmir, India, Archives of Neuroscience 7(4) (2020).
M. Ruiz, K. Floor, S. Steinberg, K. Grünberg, F.B. Thunnissen, J.A. Belien, G.A. Meijer, G.J. Peters, E.F. Smit, J.A. Rodriguez, Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients, British journal of cancer 100(1) (2009) 145-152.
M. Maqbool, A.M. Dar, S. Rasool, M. Khan, Curious case of drug resistant malaria and artemisinin compounds in the modern era, Journal of Applied Pharmaceutical Sciences and Research (2019) 1-4.
G. Fekadu, F. Bekele, K. Bekele, S. Hanbisa, G. Belay, M. Maqbool, Drug Use Evaluation of Beta-Blockers in Medical Wards of Nedjo General Hospital, Western Ethiopia, Cardiovascular Therapeutics 2020 (2020).
M. Scartozzi, I. Bearzi, R. Berardi, A. Mandolesi, C. Pierantoni, S. Cascinu, Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options, British journal of cancer 97(1) (2007) 92-97.
M. Maqbool, N. Nasir, S. Mustafa, Polycystic in ovarian syndrome and its various treatment strategies, INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 5(9) (2018) 8470-8478.
M. Maqbool, M. Dar, S. Rasool, S. Mir, A. Bhat, M. Khan, Clinical pharmacy practice in health care system: A review, Eur J Pharm Med Res 6(4) (2019) 630-633.
L. Cheng, W. Ren, L. Xie, M. Li, J. Liu, J. Hu, B.-R. Liu, X.-P. Qian, Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories, Cancer chemotherapy and pharmacology 74 (2014) 1-13.
M. Wu, P. Zhang, EGFR-mediated autophagy in tumourigenesis and therapeutic resistance, Cancer letters 469 (2020) 207-216.
L. Goyal, M.D. Muzumdar, A.X. Zhu, Targeting the HGF/c-MET Pathway in Hepatocellular CarcinomaTargeting the HGF/c-MET Pathway in HCC, Clinical Cancer Research 19(9) (2013) 2310-2318.
M. Maqbool, A. Naeem, S. Aamer, Diabetes Mellitus and Its Various Management Strategies in Practice, Indo American Journal of Pharmaceutical Sciences 5(8) (2018) 8163-+.
J. Fu, X. Su, Z. Li, L. Deng, X. Liu, X. Feng, J. Peng, HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence, Oncogene 40(28) (2021) 4625-4651.
A. Anestis, I. Zoi, M.V. Karamouzis, Current advances of targeting HGF/c-Met pathway in gastric cancer, Annals of translational medicine 6(12) (2018).
M. Maqbool, S. Tariq, S. Amjad, Prescribing Practices in Pediatrics and Drug Utilization Studies Promoting Pediatric Health, Indo American Journal of Pharmaceutical Sciences 5(8) (2018) 8070-8076.
M.A. Dar, M. Maqbool, S. Rasool, Pharmaceutical wastes and their disposal practice in routine, Int J Inf Comput Sci 6 (2019) 76-92.
S. Rasool, M. Maqbool, Y. Joshi, Drug utilization studies among ENT patients in various clinical settings: A comprehensive review, Journal of Drug Delivery and Therapeutics 9(1-s) (2019) 481-485.
A. de Gramont, A. de Gramont, B. Chibaudel, J.-B. Bachet, A.K. Larsen, C. Tournigand, C. Louvet, T. André, From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer, Seminars in oncology, Elsevier, 2011, pp. 521-532.
T. Connors, R. Duncan, R. Knox, The chemotherapy of colon cancer, European Journal of Cancer 31(7-8) (1995) 1373-1378.
J. Li, N. Hou, A. Faried, S. Tsutsumi, H. Kuwano, Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model, European journal of cancer 46(10) (2010) 1900-1909.
M. Maqbool, M.A. Dar, S. Rasool, I. Gani, M. Khan, Substance use disorder and availability of treatment options: an overview, Journal of research in health science 1 (2019) 4-10.
S.A. Bhat, S.A. Mir, M. Maqbool, A.U. Bhat, M.H. Masoodi, Evaluation of phytochemical, antioxidant, and in-vitro antidiarrhoeal, activity of Euphorbia hirta, Journal of Drug Delivery and Therapeutics 9(1-s) (2019) 290-294.
R. Xu, N. Sato, K. Yanai, T. Akiyoshi, S. Nagai, J. Wada, K. Koga, R. Mibu, M. Nakamura, M. Katano, Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells, Anticancer research 29(1) (2009) 261-270.
S. Tripathi, L. Belkacemi, M.S. Cheung, R.N. Bose, Correlation between gene variants, signaling pathways, and efficacy of chemotherapy drugs against colon cancers, Cancer Informatics 15 (2016) CIN. S34506.
M. Maqbool, S. Javed, A.A. Bajwa, Assessment OF pain management IN postoperative cases using different scales and questionnaires, INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 6(1) (2019) 983-987.
R. Bashir, M. Maqbool, I. Ara, M. Zehravi, An In sight into Novel Drug Delivery System: In Situ Gels, CELLMED 11(1) (2021) 6.1-6.7.
G. Fekadu, B. Gamachu, T. Mengie, M. Maqbool, Knowledge, attitude of health care professional’s towards clinical pharmacy services in Nedjo General Hospital, Western Ethiopia, International Journal 5(7) (2019) 172.
I. Ara, M. Zehravi, M. Maqbool, I. Gani, A Review of Recent Developments and Future Challenges in the Implementation of Universal Health Coverage Policy Framework in Some Countries, Journal of Pharmaceutical Research & Reports. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3) 127 (2022).
Published
Issue
Section
License
Copyright (c) 2023 Mohd Altaf Dar, Aslam Hamid Khan, Mashooq Ahmad Mir, Abrar Bashir Malik
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
